Mark S. Litwin mainly investigates Prostate cancer, Internal medicine, Surgery, Prostatectomy and Quality of life. The various areas that he examines in his Prostate cancer study include Sexual function, Prostate, Radiation therapy and Gynecology. In his study, which falls under the umbrella issue of Internal medicine, Epidemiology of cancer is strongly linked to Oncology.
His study in Surgery is interdisciplinary in nature, drawing from both Kidney cancer, Renal cell carcinoma, Nephrectomy and Cystoscopy. His Prostatectomy research integrates issues from Logistic regression, Brachytherapy, Medicare beneficiary, Intensive care medicine and Prostate-specific antigen. His Quality of life study combines topics from a wide range of disciplines, such as Cross-sectional study, Physical therapy and Gerontology.
The scientist’s investigation covers issues in Prostate cancer, Internal medicine, Oncology, Prostatectomy and Gynecology. His research integrates issues of Quality of life, Quality of life, Surgery and Prostate in his study of Prostate cancer. In his research on the topic of Quality of life, Prostatitis and Chronic prostatitis/chronic pelvic pain syndrome is strongly related with Physical therapy.
His Oncology research incorporates themes from Androgen deprivation therapy and Epidemiology of cancer. His Prostatectomy research is multidisciplinary, incorporating elements of Radiation therapy, Brachytherapy, General surgery and Urology. His Gynecology study incorporates themes from Health care quality and Family medicine.
His primary areas of study are Prostate cancer, Internal medicine, Comorbidity, Oncology and Cancer. Mark S. Litwin has researched Prostate cancer in several fields, including Gynecology, Quality of life, Cohort and Family medicine. His study in the field of Bladder cancer, Prospective cohort study and Survival analysis is also linked to topics like Variation.
His biological study spans a wide range of topics, including Survival rate, Surgery, Retrospective cohort study, Gerontology and Nephrectomy. His research in Surgery intersects with topics in Cystectomy, Prostatectomy, Disease and Patient experience. His Cancer research incorporates elements of Odds ratio, Psychiatry, Epidemiology and Hazard ratio.
His main research concerns Internal medicine, Prostate cancer, Comorbidity, Cancer and Epidemiology. Mark S. Litwin has included themes like Perioperative and Oncology in his Internal medicine study. Mark S. Litwin interconnects Prospective cohort study, Gynecology, Quality of life and Cohort in the investigation of issues within Prostate cancer.
His Quality of life study integrates concerns from other disciplines, such as Urinary system and Brachytherapy. His studies deal with areas such as Stage, Surgery, Kidney cancer and Nephrectomy as well as Epidemiology. As a part of the same scientific family, Mark S. Litwin mostly works in the field of Surgery, focusing on Cystectomy and, on occasion, Disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
How to Measure Survey Reliability and Validity
Mark S. Litwin.
(1995)
Quality of life and satisfaction with outcome among prostate-cancer survivors.
Martin G. Sanda;Rodney L. Dunn;Jeff Michalski;Howard M. Sandler.
The New England Journal of Medicine (2008)
The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure
Mark S. Litwin;Mary McNAUGHTON-COLLINS;Floyd J. Fowler;J. Curtis Nickel.
The Journal of Urology (1999)
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
John T Wei;Rodney L Dunn;Rodney L Dunn;Mark S Litwin;Howard M Sandler.
Urology (2000)
Quality-of-life Outcomes in Men Treated for Localized Prostate Cancer
Mark S. Litwin;Ron D. Hays;Arlene Fink;Patricia A. Ganz.
JAMA (1995)
The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.
Mark S. Litwin;Ron D. Hays;Arlene Fink;Patricia A. Ganz.
Medical Care (1998)
The Diagnosis and Treatment of Prostate Cancer: A Review.
Mark S. Litwin;Hung-Jui Tan.
JAMA (2017)
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Christopher S. Saigal;John L. Gore;Tracey L. Krupski;Janet Hanley.
Cancer (2007)
The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Matthew R. Cooperberg;David J. Pasta;Eric P. Elkin;Mark S. Litwin.
The Journal of Urology (2005)
Comprehensive Comparison of Health-Related Quality of Life After Contemporary Therapies for Localized Prostate Cancer
John T. Wei;Rodney L. Dunn;Howard M. Sandler;P. William McLaughlin.
Journal of Clinical Oncology (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Michigan–Ann Arbor
University of California, San Francisco
University of Michigan–Ann Arbor
Cleveland Clinic
University of California, San Francisco
Vanderbilt University Medical Center
Queen's University
Cedars-Sinai Medical Center
The University of Texas MD Anderson Cancer Center
National Institutes of Health
Pennsylvania State University
Fudan University
University of Notre Dame
MIT
Lawrence Berkeley National Laboratory
Bhabha Atomic Research Center
MIT
University of Alabama at Birmingham
Dalhousie University
Swiss Federal Institute for Forest, Snow and Landscape Research
Commonwealth Scientific and Industrial Research Organisation
Los Alamos National Laboratory
AstraZeneca (United Kingdom)
University of Strasbourg
Bowling Green State University
Karolinska Institute